文献速递鼻科咽喉与嗓音

美泊利珠单抗治疗美国重症哮喘合并慢性鼻窦炎的真实世界有效性:合并症与鼻窦手术的影响

Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-07-20

本回顾性队列研究利用IQVIA PharMetrics Plus理赔数据,分析美泊利珠单抗治疗美国重症哮喘合并慢性鼻窦炎(伴或不伴鼻窦手术)患者12个月前后变化。三个队列分别纳入495例、370例和85例,用药后全身及口服糖皮质激素使用均降低,哮喘急性发作减少28%至44%,队列3(合并鼻窦手术)降幅最大。

要点

  • 美泊利珠单抗启动后所有队列全身及口服糖皮质激素使用均降低。
  • 哮喘急性发作较基线减少28%至44%,队列3降幅最大。
  • 队列3口服糖皮质激素理赔减少幅度大于队列1和队列2。

核心结论

  • 真实世界实践中美泊利珠单抗在各合并症队列均显示获益,在重症哮喘合并慢性鼻窦炎且接受鼻窦手术者中影响更明显。

研究设计与样本

  • 回顾性队列研究,使用IQVIA PharMetrics Plus理赔数据,分析美泊利珠单抗启动前12个月与后12个月数据。
  • 队列1为仅重症哮喘(495例),队列2为重症哮喘合并慢性鼻窦炎未行鼻窦手术(370例),队列3为重症哮喘合并慢性鼻窦炎且行鼻窦手术(85例)。

主要发现

  • 所有队列美泊利珠单抗启动后全身及口服糖皮质激素使用均降低。
  • 队列3随访期哮喘急救吸入剂和抗生素使用低于基线。
  • 随访期较基线哮喘急性发作减少28%至44%,队列3降幅最大(与队列1的发病率比值比之比RR为0.76;p=0.036)。
  • 美泊利珠单抗启动后口服糖皮质激素理赔减少幅度队列3大于队列1(RR 0.72;p=0.011)和队列2(RR 0.70;p<0.01)。
  • 队列1至3随访期门诊和急诊就诊每年减少1至2次和0.4至0.6次,哮喘相关及哮喘急性发作相关总费用减少387至2580美元,医疗费用减少383至2438美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trial data demonstrate that mepolizumab, a humanized anti-interleukin 5 monoclonal antibody, is effective for patients with severe asthma and comorbid chronic rhinosinusitis (CRS) with nasal polyps. This real-world, retrospective cohort study investigated mepolizumab for US patients with severe asthma and CRS with/without sinus surgery. METHODS: IQVIA PharMetrics Plus claims data from baseline and follow-up (12 months before and after mepolizumab initiation) were used to analyze three patient cohorts: cohort 1 (severe asthma only); cohort 2 (severe asthma + comorbid CRS without sinus surgery); and cohort 3 (severe asthma+comorbid CRS+sinus surgery), allowing for cross-cohort comparisons. RESULTS: The analysis included 495, 370, and 85 patients in cohort 1, cohort 2, and cohort 3, respectively. Systemic and oral corticosteroid use was lower for all cohorts after mepolizumab initiation. In cohort 3, asthma rescue inhaler and antibiotic use were lower during follow-up than baseline. Asthma exacerbations were reduced by 28% to 44% comparing follow-up versus baseline, with the largest reduction in cohort 3 (ratio of incidence rate ratio [RR] vs cohort 1: 0.76; p = 0.036). Reductions in oral corticosteroid claims were greater following mepolizumab initiation for cohort 3 versus cohort 1 (RR, 0.72; p = 0.011) and cohort 2 (RR, 0.70; p < 0.01). In cohorts 1 through 3, outpatient and emergency department visits were reduced by 1 to 2 and 0.4 to 0.6 visits annually, asthma-related and asthma exacerbation-related total costs were reduced by $387 to $2580 USD, and medical costs were reduced by $383 to $2438 USD during follow-up. CONCLUSIONS: Consistent with trial data, mepolizumab use in real-world practice shows benefits across comorbid patient cohorts with more a pronounced impact in those with severe asthma+comorbid CRS + sinus surgery.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Silver J, Deb A, Laliberté F, et al. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery. Int Forum Allergy Rhinol. 2023. PMID: 37365852. doi:10.1002/alr.23220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。